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BACKGROUND. The goals of sentinel lymph node biopsy (SLNB) are to improve
axillary staging and reduce unnecessary axillary lymph node dissections (ALND),
thereby reducing treatment-related upper-limb morbidity. In the current prospec-
tive study, short-term upper-limb morbidity was assessed after SLNB and/or
ALND.
METHODS. The study comprised 204 patients with Stage I/II breast carcinoma.
Mean patient age was 55.6 years (standard deviation, 11.6). Sixty-six patients (32%)
underwent SLNB only, and 138 (68%) underwent a Level I–II ALND. Assessment
(preoperative [t0] and 6 weeks postoperative [t1]) included evaluation of shoulder
range of motion, muscle strength, grip strength, pain, upper/forearm circumfer-
ence, shoulder disability, and activities of daily life (ADL).
RESULTS. Considerable treatment-related upper-limb morbidity was observed.
Signiﬁcant (P  0.001) changes were found for pain, range of motion in forward
ﬂexion, abduction and abduction/external rotation, strength of shoulder abductors
and elbow ﬂexors, and in perceived disability in ADL. However, no signiﬁcant
difference in change of upper-limb function and ADL was found between the SLNB
and ALND groups.
CONCLUSIONS. Signiﬁcant short-term treatment-related upper-limb morbidity ex-
ists after SLNB or ALND. There is no signiﬁcant difference in short-term treatment-
related morbidity between SLNB and ALND. Cancer 2003;98:690–6.
© 2003 American Cancer Society.
KEYWORDS: breast carcinoma, staging, sentinel lymph node, morbidity, activities of
daily life.
The incidence of breast carcinoma in The Netherlands is 100 per100,000 women per year.1 Of every 10 women, 1 will develop
breast carcinoma and 79% will survive at least 5 years.1–2
The goals of breast carcinoma treatment are local tumor control,
optimal lymph node staging with minimal treatment-related morbid-
ity, good functional results, and breast preservation. Axillary lymph
node status is the most signiﬁcant prognostic variable in patients with
breast carcinoma.3–6 Therefore, axillary lymph node dissection
(ALND) is an important diagnostic, staging, and treatment proce-
dure.7 However, ALND may result in upper-limb morbidity such as
pain, numbness, lymph edema, weakness, and impaired shoulder
range of motion.7–14 Upper-limb morbidity may interfere with the
activities of daily life (ADL) and quality of life.13–21 In the early post-
operative period, return to routine activities is usually difﬁcult be-
cause of pain and restricted range of motion of the shoulder.22,23 The
sentinel lymph node procedure was introduced recently to decrease
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the number of unnecessary ALNDs and to reduce sur-
gery-related morbidity as a result of ALND.24–27 Sen-
tinel lymph node biopsy (SLNB) removes selectively
the lymph node that receives the metastatic drainage
from the tumor. SLNB is an accepted procedure be-
cause of its accuracy to predict the presence of meta-
static disease in the axillary lymph nodes.24,25,28,29 Yet,
to our knowledge, only a few studies have been per-
formed to evaluate morbidity after SLNB.26,27,29–35 Fol-
low-up in these studies was less than 2 years and
SLNB-related morbidity seemed to be less in compar-
ison to ALND-related morbidity.26,27,30–35
Although the number of studies investigating up-
per-limb morbidity after breast carcinoma is increas-
ing, the role of SLNB in reducing upper-limb morbid-
ity and perceived disability in all postoperative phases
is still not clear.27,30,32 The aim of the current study
was to analyze prospectively the short-term upper-
limb morbidity and perceived disability in ADL of
patients after SLNB versus ALND.
MATERIALS AND METHODS
From June 1999 to June 2001, patients with Stage I
(T1N0M0: tumor 2 cm or less in greatest dimension
[T1], no regional lymph node metastasis [N0], no dis-
tant metastasis [M0]) or Stage II (T1N1M0, T2N0M0,
T2N1M0, T3N0M0: metastasis to movable ipsilateral
axillary lymph node [N1], tumor more than 2 cm but
not more than 5 cm in greatest dimension [T2], tumor
more than 5 cm in greatest dimension [T3]) breast
carcinoma participated in a cohort study to assess
treatment-related upper-limb morbidity.36 Patients
were retrieved from two hospitals. The Groningen
University Hospital already had been using SLNB in its
staging procedure whereas the Martini Hospital Gro-
ningen introduced SLNB halfway during the inclusion
period. Informed consent was obtained from the par-
ticipating patients. The protocol was approved by the
institutional review board committees of both institu-
tions. Data regarding patient characteristics and treat-
ment variables were collected from the medical
records. Two groups of patients were distinguished in
the current study: patients who underwent SLNB and
patients who underwent ALND or ALND after SLNB.
Sentinel lymph nodes were identiﬁed using both a
radioactive tracer and Patent blue dye (Blue Patente´ II;
Labatoire Guerbet, Aulnay-sous-Bois, France). If me-
tastases were identiﬁed in the sentinel lymph node,
ALND was performed within 2 weeks after the SLNB.
The procedure has been described extensively by Rut-
gers et al.37 ALND consisted of a Level I–II axillary
dissection. Contemporary surgical treatment included
a modiﬁed radical mastectomy or breast-conserving
treatment.
Upper-limb function and ADL were evaluated 1
day before surgery (t0) and 6 weeks after surgery (t1).
Pain was assessed with a visual analog scale (VAS;
Table 1). Patients were asked to mark their current
pain perception on a 10 cm straight line (0 cm  no
pain, 10 cm worst pain imaginable).38,39 Upper-limb
function was assessed during a standardized physical
examination (Table 1). Active shoulder range of mo-
tion was measured with a goniometer according to a
standardized protocol in forward ﬂexion, abduction,
and external rotation.40,41 The muscle strength of the
shoulder abductors and elbow ﬂexors was measured
using a hand-held dynamometer (Citec; Groningen,
The Netherlands)42–44 and grip strength was measured
with a Yamar (Bollingbrook, IL) hand-dynamome-
ter.15,45 All muscle strength measurements were per-
formed three times and the mean of these three mea-
surements was used for further analysis. Upper and
forearm circumference was measured with a Gulick
measuring tape at 10 cm proximal to the olecranon
and 15 cm proximal to the processus styloideus ulnae.
ADL was assessed with the Shoulder Disability
Questionnaire (SDQ) and the Groningen Activity Re-
TABLE 1
Assessment of Shoulder Function and Activities of Daily Life
Assessment Assessment tool
Shoulder function
Pain (current pain) VASa (cm)
Numbness Clinical examination: numbness
(yes or no)
Active shoulder range of motion
Forward ﬂexion Isomed inclinometerb (°)
Abduction Isomed inclinometerb (°)
External rotation Isomed inclinometerb (°)
Combined abduction/external rotation Isomed inclinometerb (°)
Muscle strength
Shoulder abductors Citec hand-held dynamometer.
(Newton-meters)c
Elbow ﬂexors Citec hand-held dynamometer
(Newton-meters)42–44
Grip strength (cylinder grip) Yamar hand-dynamometer
(Newton-meters)d
Upper arm circumference 10 cm proximal to the olecranone
Fore arm circumference 15 cm proximal to the processus
styloideus ulnaee
ADL SDQf and GARSg
VAS: visual analog scale; cm: centimeters; °: degrees; ADL: activities of daily life; SDQ: Shoulder
Disability Questionnaire; GARS: Groningen Activity Restriction Scale.
a See Hladink et al., 1992,38 and Jensen et al., 1986.39
b See Gerber et al., 1992,40 and Green et al., 1998.41
c See Van der Ploeg, 199242; Van der Ploeg et al., 199143; and Balogun et al., 1998.44
d See Swedborg et al., 1981,15 and Mathiowetz et al., 1984.45
e Measured with the Gulick measuring tape (Lafayette Instruments, model 258-J00305).
f See Van der Heijden, 1996,46 and Van der Heijden et al., 2000.47
g See Kempen et al., 1996,48 and Suurmeijer et al., 1994.49
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striction Scale (GARS). The 16-item SDQ is a func-
tional status measure that evaluates the ability of pa-
tients with shoulder disorders to perform daily
activities.46,47 The SDQ contains 16 statements that
describe the situations in which patients experience
pain and what some of the effects may be. It has a
three-category response format (e.g., 1: yes my shoul-
der is painful when I open or close a door; 2: no my
shoulder is not painful when I open or close a door; 3:
I did not perform the activity during the past 24 hours).
The total score for the 16 statements ranges from 0 (no
functional status limitation) to 100 (maximum func-
tional status limitation) (Table 1).46,47 The GARS as-
sesses the perceived restrictions (disability) in per-
forming 18 ADL.48,49 It has a four-category response
format (1: able to perform the activity without any
difﬁculty; 2: able to perform the activity with some
difﬁculty; 3: able to perform the activity with much
difﬁculty; 4: unable to perform the activity indepen-
dently). The sum score ranges from 18 (the person can
perform all the activities without any difﬁculty) to 72
(the person cannot perform any activity without the
help of others; Table 1).48,49
Statistical analyses were performed using descrip-
tive statistics and t tests for independent samples for
between-group comparisons and t tests for dependent
samples for within-group comparisons. Differences
were accepted as signiﬁcant if P values were less than
0.05.
RESULTS
During 2 years (1999–2001), 208 consecutive patients
with invasive breast carcinoma entered the study.
Their mean age was 55.6 years (standard deviation
[SD], 11.6). Forty-two percent had Stage I disease (n
 87), 41% had Stage IIA disease (n  86), and 17%
had Stage IIb disease (n  35). One patient was ex-
cluded from the study because she had a prophylactic
mastectomy due to a positive family history for breast
carcinoma. Three patients canceled follow-up ap-
pointments before t1. One patient was treated else-
where, and the other two found the assessment pro-
tocol bothersome and chose to withdraw from the
study.
Two hundred four patients completed preopera-
tive and postoperative assessments. Initially, 124
(61%) patients underwent a SLNB. Of these patients,
58 (47%) had metastatic disease in the sentinel lymph
node(s) and additional ALND was performed. There-
fore, the study comprised 66 patients with SLNB (32%)
and 138 patients with a Level I–II ALND (68%; Fig. 1).
Of the 66 patients with SLNB, 17 patients received
a mastectomy (26%) and 49 patients received breast-
conserving treatment (74%). In the ALND group (n
 138), 68 patients received a mastectomy (49%) and
70 patients received breast-conserving treatment
(51%).
Postoperative complications were scored in both
groups. Serome production that lasted longer than 4
weeks was reported in 3 of 60 patients with SLNB (5%)
and in 18 of 119 patients with ALND (15%; P  0.051).
Inﬂammation of the wound that necessitated antibi-
otic treatment occurred in 6 of 63 patients with SNLB
(10%) and in 20 of 121 patients with ALND (17%),
which was not signiﬁcant (P  0.265).
Signiﬁcant treatment-related upper-limb morbid-
ity and disability 6 weeks after surgery included pain,
decreased range of motion in forward ﬂexion, abduc-
tion, and abduction/external rotation, and loss of
strength of shoulder abductors and elbow ﬂexors (Ta-
ble 2). The self-assessed perception of pain (VAS) in-
creased from 0.5 (SD, 1.2) preoperatively to 1.3 (SD,
1.3) 6 weeks postoperatively (P 0.001) (Table 2). One
hundred thirty-eight patients(67.6 %) perceived post-
operative numbness of the axillary region.
The largest decrease in range of motion of the
shoulder was found in abduction (25.9 °, SD: 38.9) but
there also was a signiﬁcant decrease (P  0.001) in the
range of motion for forward ﬂexion (11.2 °, SD: 21.2)
and abduction/external rotation (8.2 °, SD: 17.4). No
change in range of motion was observed for the exter-
nal rotation alone. Considerably decreased muscle
strength in the shoulder abductors (16.9 Newton-
meters [Nm]; SD, 52.3) and elbow ﬂexors (15.1 Nm;
SD, 58.9) was observed. Although grip strength de-
creased by 12.3 Nm (SD, 89.9) postoperatively, this
decrease was not signiﬁcant. The circumferences of
the forearm and upper arm as measured 6 weeks after
surgical treatment had not changed signiﬁcantly (Ta-
ble 2).
The SDQ and GARS found increased disability
among the breast carcinoma patients. The change on
the SDQ (15.4; SD, 34.6 [on a scoring range from
0–100]) was larger than the change assessed with the
GARS (4.6; SD, 7.3 [on a scoring range from 18–72])
(Table 2).
FIGURE 1. Diagram of patients included in the study. SLNB: sentinel lymph
node biopsy; ALND: axillary lymph node dissection.
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The increase in perceived disability between t0
and t1 was correlated signiﬁcantly with the increase in
pain (VAS) between t0 and t1 (Pearson correlation
VASt1–t0 and SDQt1–t0  0.561, Pearson correlation
VASt1–t0 and GARSt1–t0 0.422). Other aspects of upper
arm morbidity (e.g., decreased shoulder range of mo-
tion and loss of strength) were not correlated signiﬁ-
cantly with an increase in perceived disability. None of
the assessments of the noninvolved side changed sig-
niﬁcantly between t0 and t1.
Changes in upper-limb function (upper-limb
morbidity) and ADL (perceived disability) between t0
and t1 were not signiﬁcantly different between the
SLNB group and the ALND group (Table 3). Although
almost all assessed items of upper-limb function and
ADL changed slightly more in the ALND group com-
pared with the SLNB group, none of these differences
were signiﬁcant.
Numbness was observed in 42 patients in the
SLND group (64%) and in 96 patients in the ALND
group (70%) at t1 (P  0.519). The changes in upper-
limb function and ADL between t0 and t1 for patients
TABLE 2




postoperative) Change (t1  t0)
PMean SD Mean SD Mean SD
Pain (VAS: 0–10) 0.5 1.2 1.3 2.0 0.8 2.1 0.000
Forward ﬂexion (°) 172.9 11.1 161.7 17.9 11.2 21.2 0.000
Abduction (°) 168.1 21.6 142.2 34.1 25.9 38.9 0.000
Abduction/external rotation (°) 87.1 6.5 78.9 16.0 8.2 17.4 0.000
External rotation (°) 67.8 13.3 66.8 12.9 1.0 18.5 0.414
Grip strength (Nm) 289.5 63.3 277.2 65.2 12.3 89.9 0.059
Strength of shoulder abductors (Nm) 149.9 35.9 133.0 39.9 16.9 52.3 0.000
Strength of elbow ﬂexors (Nm) 178.8 42.0 163.7 41.3 15.1 58.9 0.000
Circumference of upper arm (cm) 26.7 3.1 27.0 3.2 0.3 4.3 0.243
Circumference of forearm (cm) 24.2 2.1 24.3 2.2 0.1 2.9 0.484
SDQ (0–100) 8.7 20.2 24.1 30.2 15.4 34.6 0.000
GARS (18–72) 19.8 4.0 24.2 6.6 4.6 7.3 0.000
SD: standard deviation; VAS: visual analog scale; Nm: Newton-meters; cm: centimeters; °: degrees; SDQ: Shoulder Disability Questionnaire; GARS: Groningen Activity Restriction Scale.
TABLE 3
Changes in Upper-Limb Function and Disability in the Sentinel Lymph Node Biopsy and Axillary Lymph Node
Dissection Groups: Results of t Tests for Independent Samples
Characteristic
SLNB (t1  t0) (n  66)
ALND (t1  t0)
(n  138)









Pain (VAS: 0–10) 1.1 2.1 1.3 2.0 0.2 0.3 0.528
Forward ﬂexion (°) 10.3 15.8 11.5 23.4 1.2 2.9 0.680
Abduction (°) 24.7 40.6 26.4 38.4 1.7 6.0 0.774
Abduction/external rotation (°) 7.2 13.1 8.7 19.2 1.5 2.7 0.576
External rotation (°) 2.1 19.3 0.9 18.1 1.2 2.9 0.670
Grip strength (Nm) 5.8 94.1 16.9 86.5 11.1 13.8 0.422
Strength of shoulder-abductors (Nm) 15.9 55.8 17.3 51.0 1.4 8.1 0.863
Strength of elbow-ﬂexors (Nm) 14.4 59.2 15.5 59.1 1.1 9.2 0.907
Circumference of upper arm (cm) 0.9 4.2 0.1 4.3 0.8 0.7 0.281
Circumference of forearm (cm) 0.4 3.1 0.0 2.9 0.4 0.5 0.389
SDQ (0–100) 14.3 32.3 15.7 35.8 1.4 5.3 0.789
GARS (18–72) 3.5 7.2 4.9 7.5 1.4 1.1 0.191
SLNB: Sentinel lymph node biopsy; ALND: axillary lymph node dissection; SD: standard deviation; VAS: visual analog scale; Nm: Newton-meters; cm: centimeters; ° degrees; SDQ: Shoulder Disability Questionnaire;
GARS: Groningen Activity Restriction Scale.
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who received breast-conserving therapy or a modiﬁed
radical mastectomy also were assessed (data not
shown). No signiﬁcant differences in upper-limb func-
tion and ADL were documented for these two groups.
In a post hoc analysis, patients who underwent breast-
conserving therapy (n  119) were selected to analyze
in a homogeneous group, the inﬂuence of SLNB and
ALND on the outcome variables. In the t test for in-
dependent samples, no signiﬁcant difference in
change in upper-limb function or ADL was found be-
tween the groups (data not shown).
DISCUSSION
The current study showed that there is signiﬁcant
short-term upper-limb morbidity and associated ADL
disabilities in patients with breast carcinoma who un-
dergo SLNB and/or ALND. However, no signiﬁcant
differences in short-term upper-limb morbidity and
ADL disabilities were found between the SLNB and
ALND groups.
This outcome contradicts the assumption that
SLNB, a much less extensive procedure compared
with ALND, is associated with less upper-limb mor-
bidity than ALND. To our knowledge, only three other
studies have reported morbidity results after a rela-
tively short follow-up period after SLNB and
ALND.32–34 Baron et al.32 and Temple et al.33 used a
self-constructed instrument (i.e., the Breast Sensation
Assessment Scale) to assess sensory morbidity. Al-
though the authors reported some difference in prev-
alence of breast sensations between SLNB and ALND
at baseline (3–15 days postsurgery) and 3 months
postsurgery, the difference was signiﬁcant for only 5 of
the 18 sensations. When women reported sensations
as severe or very severe, a signiﬁcant difference in
prevalence was only present for 3 of the 18 sensations
(speciﬁcally, numbness, stiffness, and tingling).32
Swenson et al.34 assessed the side effects of both
procedures with a self- constructed questionnaire (i.e.,
the Measure of Arm Symptom Survey) at 1, 6, and 12
months postsurgery. They found signiﬁcant differ-
ences in perceived pain, numbness, limitation in
range of motion, and interference with daily life be-
tween patients with ALND and patients with SLNB at
1 month postsurgery. This difference in occurrence of
side effects in favor of the SLNB patients continued at
6 and 12 months postsurgery, with the exception of
interference in daily life.
In contrast to the three previous studies,32–34 the
current study used a preoperative baseline assess-
ment. In addition, several reliable and validated
objective assessment tools were used and the inﬂu-
ence of short-term upper-limb morbidity on ADL
was assessed.15,38–49 In a recent systematic review,14
the importance of the baseline assessment against
which to compare the follow- up assessment was
emphasized.14 Using this baseline assessment, pos-
sible disturbances in the cause-and-effect relation
were ruled out and therefore only the postoperative
changes in upper-limb function and ADL were re-
ported.
A potential limitation of the current study is that
contemporary treatment options (mastectomy/
breast-conserving surgery) were not divided equally
between the SLNB and ALND groups. However, a post
hoc analysis of the inﬂuence of SLNB and ALND on
the outcome variables in only the breast-conserving
treatment group showed no signiﬁcant differences in
the occurrence of upper-limb morbidity and ADL dis-
abilities (data not shown). Other potential confound-
ers such as adjuvant radiotherapy and chemotherapy
had no inﬂuence on the study outcome because they
were started after the postoperative (t1) assessment.
A power analysis was not performed before the
study. However, if the small differences in change
between the groups (SLNB and ALND) became signif-
icant in a much larger study, the clinical relevance of
these small differences would be questioned. In addi-
tion, because the SLNB procedure is a relatively new
technique, no data were available to perform an ade-
quate power analysis before the current study.
No signiﬁcant difference in the prevalence of
numbness between the SLNB and ALND group was
documented, which is in contrast to other stud-
ies.26,32–35 The high numbness score among the SLNB
patients cannot be explained.
A signiﬁcant change in upper-limb function and
ADL after SLNB or ALND was found in the current
study. However, the overall upper-limb morbidity and
associated disability in ADL was low. Speciﬁc shoul-
der-related disability in ADL (SDQ) was more affected
than overall ADL (GARS). Pain was the only impair-
ment that correlated signiﬁcantly with perceived dis-
ability postsurgery (Pearson correlation VASt1–t0 and
SDQt1–t0  0.561, Pearson correlation VASt1–t0 and
GARSt1–t0  0.422). Although there are signiﬁcant but
rather small mean differences in upper-limb function
(e.g., decreased forward ﬂexion, abduction, decreased
strength of shoulder abductors and elbow ﬂexors),
these differences were not clinically relevant in rela-
tion to perceived disabilities in ADL 6 weeks postsur-
gery.
In conclusion, signiﬁcant short-term treatment-
related upper-limb morbidity and associated ADL dis-
abilities exist after SLNB or ALND. There is no signif-
icant difference in short-term treatment-related
morbidity between SLNB and ALND.
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